Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue 2, 2008, Pages 123-132

  El Ibiary, Shareen Y ^a   Cocohoba, Jennifer M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug interactions; HIV antiretrovirals; Hormonal contraceptives

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; EFAVIRENZ; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEDROXYPROGESTERONE; NELFINAVIR; NEVIRAPINE; PLACEBO; PROGESTERONE; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HORMONAL CONTRACEPTION; HORMONE DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LOW DRUG DOSE; MEDICAL RESEARCH; PATIENT COUNSELING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TIME SERIES ANALYSIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; FEMALE; HUMANS;

EID: 47349093975     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701829952     Document Type: Article

References (36)

1. UNAIDS. 2006 Report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition, 2006.
2. Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. Aids 2004;18:281-6.
3. van Benthem BH, de Vincenzi I, Delmas MC, et al. Pregnancies before and after HIV diagnosis in a European cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. Aids 2000;14:2171-8.
4. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:90-6.
5. http://www.aidsinfo.nih.gov/guidelines/adult/AA_100606.pdf. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, US Department of Health and Human Services; Accessed 10 October 2006, p. 35.
6. Speroff LDP. A clinical guide to contraception. Philadelphia, PA: Lippincott, Williams, &Wilkins, 2001.
7. Hatcher R, Trussell J, Stewart F, et al. Contraceptive technology. New York, NY: Ardent Media Inc., 2004.
8. Brunton L, Lazo JS, Parker KL. Goodman and Gillman's pharmacological basis of therapeutics. New York, NY: McGraw-Hill Publishing, 2005.
9. Cavallari L, Ellingrod VL, Kolesar JM. Lexi-Comp's pharmacogenomics handbook. Hudson, OH: Lexi-Comp Inc., 2005.
10. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
11. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
12. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601.
13. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:203-9.
14. Cohn S, Watts D, Lertora J, et al. An open-label, non-randomized study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics (PK) of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA. 22-25 February 2005. Abstract 82.
15. Cohn SE, Park JG, Watts DH, et al. Depomedroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007;81:222-7.
16. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002;29:471-7.
17. Laboratories A. Norvir (ritonavir) package insert. North Chicago, IL, 2006.
18. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.
19. Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004;57:244-52.
20. GlaxoSmithKline. Lexiva (fosamprenavir) package insert. Research Triangle Park, NC, 2004.
21. GlaxoSmithKline. Agenerase (amprenavir) package insert. Research Triangle Park, NC, 2004.
22. Tackett D, Child M, Argawala S, et al. Atazanavir: A summary of two pharmacokinetic drug interaction studies in healthy subjects, 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10-14 February 2003.
23. Squibb BM. Reyataz (atazanavir) product package insert. Princeton, NJ, 2006.
24. Squibb BM. Sustiva (efavirenz) product package insert. Princeton, NJ.
25. Joshi A, Fiske W, Benedek I, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1-5 February 1998. Abstract 348.
26. Company M. Crixivan (indinavir) package insert. Whitehouse Station, NC, 2003.
27. Laboratories A. Kaletra (lopinavir/ritonavir) package insert. North Chicago, IL, 2004.
28. Pharmaceuticals P. Selzentry (maraviroc) package insert. New York, NY, 2007.
29. Pharmaceuticals A. Viracept (nelfinavir) package insert. La Jolla, CA, 2003.
30. Pharmaceuticals G. Viread (tenofovir) product package insert.
31. Back DJ, Burger DM, Flexner CW, et al. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing. J Acquir Immune Defic Syndr 2005;39(Suppl. 1):S1-23, quiz S24-25.
32. Ingelheim B. Aptivus (tipranavir) product package insert.
33. Tibotec. Prezista (darunavir) product package insert.
34. World Health Organization. Chronic HIV Care with ARV Therapy and Prevention. July 2006. Available at: http://www.who.int/3by5/publications/ documents/chronCareModGenDraftRev1.pdf. Accessed 20 August 2007.
35. Wilson TE, Koenig LJ, Walter E, et al. Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: The importance of an event-level focus for promoting safer sexual behaviors. Sex Transm Dis 2003;30:809-12.
36. Wilson TE, Koenig L, Ickovics J, et al. Contraception use, family planning, and unprotected sex: Few differences among HIV-infected and uninfected postpartum women in four US states. J Acquir Immune Defic Syndr 2003;33:608-13.